First-time use of newer oral contraceptives and the risk of venous thromboembolism

Contraception

Volumn 56, Issue 3, 1997, Pages 141-146

  Suissa, Samy ^a   Blais, Lucie ^a   Spitzer, Walter O ^a   Cusson, Jean ^b   Lewis, Michael ^c   Heinemann, Lothar ^c  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Potsdam Inst P   (Germany)

Author keywords

Deep venous thrombosis; Epidemiological study; Pulmonary embolism; Second generation oral contraceptives; Third generation oral contraceptives

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG USE; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; RISK; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0030764967     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00119-4     Document Type: Article

References (22)

1. Bloemenkamp KWM, Rosendaal FR, Hemerhosrt FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.
2. Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.
3. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components [see also comments]. Lancet 1995;346:1589-93.
4. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women [see also comments]. Br Med J 1996;312:83-8.
5. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception [see also comments]. Lancet 1995;346:1575-82.
6. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progrestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346: 1582-8.
7. Poulter NR, Farley TMM, Chang CL, Marmot MG, Meirik O. Safety of combined oral contraceptive pills (letter). Lancet 1996;347:547.
8. Farley TMM, Meirik O, Poulter NR, Chang CL, Marmot MG. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies (letter). Contraception 1996;54:193-8.
9. Vandenbroucke JP, Rosendaal FR. End of the line for "third-generation-pill" controversy? Lancet 1997;349: 1113-4.
10. Lidegaard O, Milsom I. Oral contraceptives and thrombotic diseases: impact of new epidemiological studies. Contraception 1996;53:135-9.
11. Rosenberg L, Bégaud B, Bergman U, et al. What are the risks of third-generation oral contraceptives? Are third-generation oral contraceptives safe? Human Reprod 1996;11:687-93.
12. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996;54:5-13.
13. rd generation progestogens) and the incidence of thromboembolism. Horm Metab Res 1996;28:245-7.
14. Rothman KJ. Modern Epidemiology. Boston: Little, Brown and Company, 1986.
15. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis [see also comments]. Epidemiology 1995;6:356-65.
16. SAS/STAT Software. Changes and Enhancements. Release 6.11 ed. Cary, NC: SAS Institute Inc., 1996.
17. Statistical Sciences. S-PLUS Version 3.3. Seattle, WA: StatSci, a division of MathSoft, Inc., 1995.
18. Guess HA. Behavior of the exposure odds ratio in a case-control study when the hazard function is not constant over time. J Clin Epidemiol 1989;42:1179-84.
19. Miettinen OS, Caro JJ. Principles of non-experimental assessment of excess risk, with special reference to adverse drug reactions. J Clin Epidemiol 1989;42:325-31.
20. Joseph KS. The evolution of clinical practice and time trends in drug effects. J Clin Epidemiol 1994;47:593-8.
21. Heinemann LAJ, Lewis MA, Assmann A, Gravens L, Guggenmoos-Holzmann I. Could preferential prescribing and referral behaviour of physicians explain the elevated thrombosis risk found to be associated with third generation oral contraceptives? Pharmacoepidemiology 1996;5:285-94.
22. Petri H, Urquhart J. Channelling bias in the interpretation of drug effects. Statist Med 1991;10:577-81.